Answers are grounded in this paper and cite their sources.
Retrospective cohort study compares drug persistence in antihistamine-refractory chronic urticaria, suggesting biomarker roles.
BACKGROUND: Real-world comparative data on alternatives to omalizumab for antihistamine-refractory chronic spontaneous urticaria (CSU) are limited, particularly in resource-constrained Asia-Pacific settings. OBJECTIVE: To compare drug survival among patients treated with omalizumab, cyclosporine, or hydroxychloroquine and evaluate associations between biomarkers and treatment persistenceใ. METHODS: This retrospective single-center cohort of 409 patients (omalizumab n = 97, cyclosporine n = 85, hydroxychloroquine n = 227) analyzed drug survival using Kaplan-Meier analysis and Cox regression. Patients were stratified by total IgE and autoimmune biomarkers (antinuclear antibodies [ANA], thyroid autoantibodies). RESULTS: Omalizumab showed significantly longer drug survival than hydroxychloroquine (hazard ratio [HR] 0.65, 95% confidence interval [CI] 0.50-0.85), while cyclosporine did not retain significance after multivariable adjustment. After stratification by potential biomarkers, omalizumab demonstrated significantly longer drug survival than hydroxychloroquine in patients with elevated total IgE (HR 0.48, 95% CI 0.32-0.72), negative ANA (HR 0.63, 95%CI 0.45-0.88), or negative IgG thyroid autoantibodies (HR 0.58, 95% CI 0.37-0.93). In patients with normal total IgE levels, no significant differences in drug survival were observed among the three treatments (p = 0.795). Hydroxychloroquine showed drug survival comparable to cyclosporine irrespective of ANA status and among patients with IgG thyroid autoantibodies. CONCLUSIONS: While omalizumab demonstrated longer overall drug survival, our findings suggest that in patients with normal total IgE or positive autoimmune biomarkers, hydroxychloroquine and cyclosporine may offer comparable drug persistence. These observations warrant prospective validation and suggest the potential value of biomarker-informed treatment approaches in resource-limited Asia-Pacific settings.
No takes yet. Share an insight, caveat, or question.
Sheu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: